Thrombosis and Cancer: About the Experience of a French Cancer Center
Institut De Cancerologie Du Gard, Rue du Professeur Henri Pujol, Nîmes Cédex 9, 30900, France
- *Corresponding Author:
- Florence Lai-Tiong
Institut De Cancerologie Du Gard
Rue du Professeur Henri Pujol
Nîmes Cédex 9, 30900, France
E-mail: [email protected]
Received date: April 26, 2016; Accepted date: June 13, 2016; Published date: June 20, 2016
Citation: Lai-Tiong F (2016) Thrombosis and Cancer: About the Experience of a French Cancer Center. J Thrombo Cir 2:110. doi: 10.4172/jtcoa.1000110
Copyright: © 2016 Lai-Tiong F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cancers and their treatments are risk factors for venous thromboembolism. The absolute risk depends on the tumor type, the stage, treatments with anti neoplasic agents. We report the results our retrospective study conducted in 2012, in our cancer center in France. The objectives were to describe the characteristics of patients diagnosed with venous thromboembolism. A total of 41 patients were enrolled: 26 women and 15 men. Median age was 61,6 years. Patients had genito-urinary malignancies for 13 of them, 13 had gynecological cancers, 4 gastro-intestinal cancers, 4 pulmonary or head and neck cancers. Patients were at metastatic stage in 29 cases and 38 received chemotherapy. For 15 patients, thrombosis was revealed by oedema and 10 patients had no symptoms. Pulmonary embolism was diagnosed in 13 patients. More research are needed to estimate the risk of thromboembolic disease in cancer patients and better understand interactions between cancer and blood coagulation, and subsequently to improve the management of the disease.